ArticleJournal of clinical neurology (Seoul, Korea)2017
Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria.
Article in Journal of clinical neurology (Seoul, Korea), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- MOG-IgG Positivity Does Not Equal MOGAD: Diagnostic Pitfall and Misapplication of the International MOGAD Panel Proposed Criteria in Real-World Practice.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies.Annals of clinical and translational neurology · 2025Article
- HLA Association With AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder in the Korean Population.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.JAMA neurology · 2025Article
- Characteristics of recurrence in area postrema-onset NMO spectrum disorder - a retrospective cohort study.BMC neurology · 2024Article
- How to improve the sensitivity and specificity of cell-based assays in detecting autoantibodies in neuroimmune diseases.Annals of translational medicine · 2023Review
- Onset of various CNS inflammatory demyelination diseases following COVID-19 vaccinations.Multiple sclerosis and related disorders · 2022Article
- Seroprevalence of anti-myelin oligodendrocyte glycoprotein antibodies in adults with myelitis.Annals of clinical and translational neurology · 2022Article
- CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage.Journal of neuroinflammation · 2022Article
- An Update on the Laboratory Diagnosis of Neuromyelitis Optica Spectrum Disorders.Journal of clinical neurology (Seoul, Korea) · 2022Review
- Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Value of Area Postrema Syndrome in Differentiating Adults With AQP4 vs. MOG Antibodies.Frontiers in neurology · 2020Article
- Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.Journal of clinical neurology (Seoul, Korea) · 2020Article
- Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Article
- Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder.Journal of neuroinflammation · 2017Article
- Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations.Neuropsychiatric disease and treatment · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe detection of aquaporin 4-IgG (AQP4-IgG) is now a critical diagnostic criterion for neuromyelitis optica spectrum disorder (NMOSD). To evaluate the serostatus of NMOSD patients based on the 2015 new diagnostic criteria using a new in-house cell-based assay (CBA).
methodsWe generated a stable cell line using internal ribosome entry site-containing bicistronic vectors, which allow the simultaneous expression of two proteins (AQP4 and green fluorescent protein) separately from the same RNA transcript. We performed in-house CBA using serum from 386 patients: 178 NMOSD patients diagnosed according to the new diagnostic criteria without AQP4-IgG, 63 high risk NMOSD patients presenting 1 of the 6 core clinical characteristics of NMOSD but not fulfilling dissemination in space, and 145 patients with other neurological diseases, including 66 with multiple sclerosis. The serostatus of 111 definite and high risk NMOSD patients were also tested using a commercial CBA kit with identical serum to evaluate the correlation between the 2 methods. All assays were performed by two independent and blinded investigators.
resultsOur in-house assay yielded a specificity of 100% and sensitivities of 80% (142 of 178) and 76% (48 of 63) when detecting definite- and high risk NMOSD patients, respectively. The comparison with the commercial CBA kit revealed a correlation for 102 of the 111 patients: no correlation was present in 7 patients who were seronegative using the commercial method but seropositive using the in-house method, and in 2 patients who were seropositive using the commercial method but seronegative using the in-house method.
conclusionsThese results demonstrate that our in-house CBA is a highly specific and sensitive method for detecting AQP4-IgG in NMOSD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.